Lowest Price Guaranteed
Slides
207
Last Updated
July 2026
View Count
12223
SECTION I: REPORT OVERVIEW
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Introduction
2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative
2.4.2.3. Advantages
2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions
2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers
2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity
2.4.3. Analytical Tools and Databases
3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics
SECTION II: QUALITATIVE INSIGHTS
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Peptide Receptor Radionuclide Therapy
6.2.1. Types of Peptide Receptor Radionuclide Therapy
6.2.2. Benefits of the Peptide Receptor Radionuclide Therapy
6.2.3. Challenges Associated with Peptide Receptor Radionuclide Therapy
6.3. Future Perspective
7. REGULATORY SCENARIO
SECTION III: MARKET OVERVIEW
8. COMPREHENSIVE DATABASE OF LEADING PLAYERS
9. COMPETITIVE LANDSCAPE
9.1. Chapter Overview
9.2. Peptide Receptor Radionuclide Therapy: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters
9.2.4. Peptide Receptor Radionuclide Therapy: Overall Market Landscape
9.2.4.1. Analysis by Isotope Type
9.2.4.2. Analysis by Indication Type
9.2.4.3. Analysis by Distribution Channel
10. PORTER'S FIVE FORCES ANALYSIS
11. COMPETITIVE COMPETITIVENESS ANALYSIS
12. STARTUP ECOSYSTEM IN THE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY MARKET
12.1. Peptide Receptor Radionuclide Therapy: Market Landscape of Startups
12.1.1. Analysis by Year of Establishment
12.1.2. Analysis by Company Size
12.1.3. Analysis by Company Size and Year of Establishment
12.1.4. Analysis by Location of Headquarters
12.1.5. Analysis by Company Size and Location of Headquarters
12.1.6. Analysis by Ownership Structure
12.2. Key Findings
SECTION IV: COMPANY PROFILES
13. COMPANY PROFILES
13.1. Chapter Overview
13.2. Advanced Accelerator Applications
13.2.1. Company Overview
13.2.2. Company Mission
13.2.3. Company Footprint
13.2.4. Management Team
13.2.5. Contact Details
13.2.6. Financial Performance
13.2.7. Operating Business Segments
13.2.8. Product Portfolio
13.2.9. MOAT Analysis
13.2.10. Recent Developments and Future Outlook
* similar detail is presented for other below mentioned companies based on information in the public domain
13.3. Alnylam Pharmaceuticals
13.4. Arrowhead Pharmaceuticals
13.5. Cellectar Biosciences
13.6. Dicerna Pharmaceuticals
13.7. Ionis Pharmaceuticals
13.8. Shenzhen Ascentawits Pharmaceuticals Sirnaomics
13.9. Silence Therapeutics
13.10. Suzhou Ribo Life Science
SECTION V: MARKET TRENDS
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Peptide Receptor Radionuclide Therapy: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Type of Patent and Patent Publication Year
14.3.3. Analysis by Patent Application Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Individual Assignees: Analysis by Number of Patents
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Peptide Receptor Radionuclide Therapy: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Location of Headquarters of Partner
15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
15.3.7. Most Active Players: Analysis by Number of Partnerships
15.3.8. Regional Analysis
15.3.8.1. Intercontinental and Intracontinental Deals
15.3.8.2. Local and International Deals
16. GRANT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Peptide Receptor Radionuclide Therapy: Grant Analysis
16.3.1. Analysis by Year of Grant Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Support Period
16.3.4. Analysis by Support Period and Funding Institute Center
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis By Activity Code
16.3.8. Analysis by NIH Spending Category
16.3.9. Analysis by Study Section Involved
16.3.10. Popular NIH Departments: Analysis by Number of Grants
16.3.11. Analysis by Type of Recipient Organization
16.3.12. Prominent Program Officers: Analysis by Number of Grants
16.3.13. Popular Recipient Organizations: Analysis by Number of Grants
16.3.14. Popular Recipient Organizations: Analysis by Grant Amount
16.3.15. Analysis by Region of Recipient Organizations
17. FUNDING AND INVESTMENTS ANALYSIS
17.1. Funding Models
17.2. Peptide Receptor Radionuclide Therapy: Funding and Investments
17.2.1. Analysis by Year of Funding
17.2.2. Analysis of Funding Instances by Type of Funding
17.2.3. Analysis of Funding Instances by Year and Type of Funding
17.2.4. Analysis of Amount Invested by Type of Funding
17.2.5. Analysis of Funding Instances by Country
17.2.6. Most Active Players: Analysis by Amount Raised
17.3. Summary and Key Takeaways
18. CLINICAL TRIAL ANALYSIS
18.1. Analysis Methodology and Key Parameters
18.2. Peptide Receptor Radionuclide Therapy: Clinical Trial Analysis
18.2.1. Analysis by Trial Status
18.2.2. Analysis by Trial Registration Year
18.2.3. Analysis by Type of Sponsor / Collaborator
18.2.4. Analysis by Type of Study Design
18.2.5. Analysis by Registration Year and Type of Study
18.2.6. Analysis by Patient Enrollment
18.2.7. Year-wise Trend of Completed and Recruiting Trials
18.2.8. Analysis by Age Category
18.2.9. Word Cloud of Study Titles
18.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
18.2.11. Most Active Non- Industry Players: Analysis by Number of Registered Trials
18.2.12. Analysis by Trial Location
18.2.13. Analysis by Trial Status and Geography
SECTION VI: MARKET OPPORTUNITY ANALYSIS
19. GLOBAL PEPTIDE RECEPTOR RADIONUCLIDE THERAPY MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Trends Disruption Impacting Market
19.4. Demand Side Trends
19.5. Supply Side Trends
19.6. Global Peptide Receptor Radionuclide Therapy Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. Multivariate Scenario Analysis
19.7.1. Conservative Scenario
19.7.2. Optimistic Scenario
19.8. Investment Feasibility Index
19.9. Key Market Segmentations
20. MARKET OPPORTUNITIES BASED ON TYPE OF ISOTOPE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Peptide Receptor Radionuclide Therapy Market for Beta Emitters: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Peptide Receptor Radionuclide Therapy Market for Alpha Emitters: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. Data Triangulation and Validation
20.8.1. Secondary Sources
20.8.2. Primary Sources
20.8.3. Statistical Modeling
21. MARKET OPPORTUNITIES BASED ON TYPE OF DISEASE INDICATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Peptide Receptor Radionuclide Therapy Market for Prostate Cancer: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Peptide Receptor Radionuclide Therapy Market for Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NETs): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. Peptide Receptor Radionuclide Therapy Market for Other Disease Indications: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.9. Data Triangulation and Validation
21.9.1. Secondary Sources
21.9.2. Primary Sources
21.9.3. Statistical Modeling
22. MARKET OPPORTUNITIES BASED ON TYPE OF DISTRIBUTION CHANNEL
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Peptide Receptor Radionuclide Therapy Market for Hospital Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Peptide Receptor Radionuclide Therapy Market for Retail Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.8. Data Triangulation and Validation
22.8.1. Secondary Sources
22.8.2. Primary Sources
22.8.3. Statistical Modeling
23. MARKET OPPORTUNITIES FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN NORTH AMERICA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. Peptide Receptor Radionuclide Therapy Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. Peptide Receptor Radionuclide Therapy Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. Peptide Receptor Radionuclide Therapy Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.3. Peptide Receptor Radionuclide Therapy Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Data Triangulation and Validation
24. MARKET OPPORTUNITIES FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN EUROPE
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix
24.6. Peptide Receptor Radionuclide Therapy Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.1. Peptide Receptor Radionuclide Therapy Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.2. Peptide Receptor Radionuclide Therapy Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.3. Peptide Receptor Radionuclide Therapy Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.4. Peptide Receptor Radionuclide Therapy Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.5. Peptide Receptor Radionuclide Therapy Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.6. Peptide Receptor Radionuclide Therapy Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.7. Data Triangulation and Validation
25. MARKET OPPORTUNITIES FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN ASIA-PACIFIC
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix
25.6. Peptide Receptor Radionuclide Therapy Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. Peptide Receptor Radionuclide Therapy Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.2. Peptide Receptor Radionuclide Therapy Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. Peptide Receptor Radionuclide Therapy Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.4. Peptide Receptor Radionuclide Therapy Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.5. Peptide Receptor Radionuclide Therapy Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.6. Peptide Receptor Radionuclide Therapy Market in Russia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.7. Peptide Receptor Radionuclide Therapy Market in Thailand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.8. Peptide Receptor Radionuclide Therapy Market in Malaysia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.9. Peptide Receptor Radionuclide Therapy Market in Indonesia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.10. Peptide Receptor Radionuclide Therapy Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.7. Data Triangulation and Validation
26. MARKET OPPORTUNITIES FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN MIDDLE EAST AND NORTH AFRICA (MENA)
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix
26.6. Peptide Receptor Radionuclide Therapy Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. Peptide Receptor Radionuclide Therapy Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
26.6.2. Peptide Receptor Radionuclide Therapy Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. Peptide Receptor Radionuclide Therapy Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.7. Data Triangulation and Validation
27. MARKET OPPORTUNITIES FOR PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN LATIN AMERICA
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Revenue Shift Analysis
27.4. Market Movement Analysis
27.5. Penetration-Growth (P-G) Matrix
27.6. Peptide Receptor Radionuclide Therapy Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.1. Peptide Receptor Radionuclide Therapy Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.2. Peptide Receptor Radionuclide Therapy Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.3. Peptide Receptor Radionuclide Therapy Market in Rest of Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.7. Data Triangulation and Validation
28. ADJACENT MARKET ANALYSIS
SECTION VII: STRATEGIC TOOLS
29. KEY WINNING STRATEGIES
30. VALUE CHAIN ANALYSIS
31. ROOTS STRATEGIC RECOMMENDATIONS
SECTION VIII: OTHER EXCLUSIVE INSIGHTS
32. INSIGHTS FROM PRIMARY RESEARCH
33. REPORT CONCLUSION
SECTION IX: APPENDIX
34. TABULATED DATA
35. LIST OF COMPANIES AND ORGANIZATIONS
36. CUSTOMIZATION OPPORTUNITIES
37. ROOTS SUBSCRIPTION SERVICES
38. AUTHOR DETAILS